FDA approves antibody to protect infants from RSV
9 months ago
184
The U.S. Food and Drug Administration approved Nirsevimab to protect newborns from Respiratory Syncytial Virus, or RSV, on Monday. Nirsevimab, which will be sold under the brand name Beyfortus, is not a vaccine. Instead, Nirsevimab is a form of passive immunity. It’s a ready-made antibody that can bind to the virus and block it from infecting healthy cells. It will be given as a single injection to an infant before RSV season, which usually peaks in the fall and winter months. The FDA approval also allows a second injection for infants up to 24 months of age who remain vulnerable through their second RSV season.
Loading comments...
-
5:09
Chrissy Clark
13 hours agoOnlyFans Creator Claims She Was Paid To Prop Up Biden Admin
5.53K27 -
3:17
Morgonn
17 hours agoStudent Loans are CRIPPLING Gen Z! How much debt do you have???
8.26K22 -
23:53
Science & Futurism with Isaac Arthur
1 day agoStatites, Lagites, and Quasites
14.9K3 -
6:05
SaturdayMorningInspection
17 hours agoLions Pulled Off A HIGH VALUE Move
12.3K9 -
5:17
Bear Creek Arsenal
22 hours ago6.5 Grendel vs. 6mm ARC vs. .224 Valkyrie [Which is Best?]
15.5K2 -
3:36
Michael Heaver
1 day agoUK’s Block Triggers Unbelievable EU U-TURN
6.8K13 -
48:20
Crime Circus
1 day agoFlorida Man's Nightmare: The Shocking Interrogation & Wrongful Arrest
9.34K5 -
19:32
Crypto Crew University
16 hours agoWARNING: BITCOIN IS ABOUT TO DO SOMETHING THAT CAUSED HUGE CRASH LAST TIME – CAN IT BE AVOIDED
18.4K2 -
2:59:18
Fresh and Fit
10 hours agoDELUSIONAL 40 yr Old Argues Men Prefer "OLDER" Women?!
127K164 -
3:43:35
Alex Zedra
11 hours agoLIVE! Giving away an M249 SAW | PJ Party + Games
45.8K11